Zobrazeno 1 - 10 of 38 pro vyhledávání: '"M. E. Duggan"'
1
Disposition of a novel and potent αvβ3antagonist in animals, and extrapolation to man
Autor: T, Prueksaritanont, C, Fernandez-Metzler, Y, Meng, A, Barrish, W, Halczenko, S B, Rodan, J H, Hutchinson, M E, Duggan, J H, Lin
Publikováno v: Xenobiotica. 34:103-115
1. The disposition of 3-[2-oxo-3-[3-(5,6,7,8-tetrahydro-[1,8]naphthyridin-2-yl) propyl]-imidazolidin-1-yl]-3(S)-(6-methoxy-pyridin-3-yl)propionic acid (compound A), a potent and selective alpha(v)beta(3) antagonist, was characterized in several anima
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4c104e46c2b568b34b30e9bc2fcfaa5a
https://doi.org/10.1080/713767592
Zobrazit plný text záznamu
3
Total Synthesis of Brevetoxin B. 2. Second Generation Strategies and Construction of the Dioxepane Region [DEFG]
Autor: Zhen Yang, Elias A. Couladouros, Kyriacos C. Nicolaou, X.‐Y. Xiao, M. E. Duggan, J. Tiebes, Emmanuel A. Theodorakis, F. Sato, M. Sato, T. Bleckman, Floris P. J. T. Rutjes, C.-K. Hwang, H.‐M. He, Jongheon Shin
Publikováno v: Journal of the American Chemical Society. 117:10239-10251
The second generation strategy for the total synthesis of brevetoxin B (1) is presented. According to this •strategy, the heptacyclic (ABCDEFG) phosphonium iodide 4 and the tricyclic (UK) aldehyde 3 were defined as the precursors for the brevetoxin
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::917f502c0239ae7a5f8fc56ffce1360a
https://doi.org/10.1021/ja00146a009
Zobrazit plný text záznamu
4
Non-Peptide Fibrinogen Receptor Antagonists. 7. Design and Synthesis of a Potent, Orally Active Fibrinogen Receptor Antagonist
Autor: M E, Duggan, A M, Naylor-Olsen, J J, Perkins, P S, Anderson, C T, Chang, J J, Cook, R J, Gould, N C, Ihle, G D, Hartman, J J, Lynch
Publikováno v: Journal of Medicinal Chemistry. 38:3332-3341
The design, synthesis, and pharmacological evaluation of L-734,217, a potent, low-molecular weight, orally active fibrinogen receptor antagonist, is reported. A strategy for producing low-molecular weight inhibitors from the peptide c-[(Ac)CRGDC] A,
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::495f8387c2303ffd5cd7ce1418f5c538
https://doi.org/10.1021/jm00017a017
Zobrazit plný text záznamu
7
Synthesis of 5/7-, 5/8- and 5/9-bicyclic lactam templates as constraints for external beta-turns
Autor: Douglas W. Young, Heather M. E. Duggan, Peter B. Hitchcock
Publikováno v: Organicbiomolecular chemistry. 3(12)
The 5/7-, 5/8- and 5/9-bicyclic lactams 3, 17, 5 and 6 have been synthesised as single diastereoisomers by a route involving ring closing olefin metathesis. The X-ray crystal structure of the amino acid hydrochloride has been carried out and compared
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::17a8c34e7a78047e4ae29ca19eaf6325
https://pubmed.ncbi.nlm.nih.gov/16010363
Zobrazit plný text záznamu
8
Synthesis of protected gamma-carboxyglutamates and gamma-acylglutamates by rearrangement of N,N-diacylglutamates
Autor: Heather M. E. Duggan, Douglas W. Young, Anthony G. Avent
Publikováno v: Organicbiomolecular chemistry. 3(12)
A new method for gamma-acylation of protected glutamic acids, involving intramolecular rearrangement of an acyl urethane, has been devised to prepare the protected gamma-carboxyglutamates 7, 9 and 11 and the protected 4-acylglutamates 15 and 22 from
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::56ae5a63d836e08c0537e2ae2de78dc7
https://pubmed.ncbi.nlm.nih.gov/16010368
Zobrazit plný text záznamu
9
alpha(v)beta(3) Integrin antagonists as inhibitors of bone resorption
Autor: G D, Hartman, M E, Duggan
Publikováno v: Expert opinion on investigational drugs. 9(6)
The alpha(v)beta(3) integrin is a non-covalent, heterodimeric, cell-surface protein that is expressed with varying density on numerous cell types, including osteoclasts, vascular smooth muscle cells, endothelial cells and a variety of tumour cells. F
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::f3caabc85d3e2d649ec71a31f026e1e6
https://pubmed.ncbi.nlm.nih.gov/11060743
Zobrazit plný text záznamu
10
Nonpeptide alpha(v)beta(3) antagonists. 1. Transformation of a potent, integrin-selective alpha(IIb)beta(3) antagonist into a potent alpha(v)beta(3) antagonist
Autor: M E, Duggan, L T, Duong, J E, Fisher, T G, Hamill, W F, Hoffman, J R, Huff, N C, Ihle, C T, Leu, R M, Nagy, J J, Perkins, S B, Rodan, G, Wesolowski, D B, Whitman, A E, Zartman, G A, Rodan, G D, Hartman
Publikováno v: Journal of medicinal chemistry. 43(20)
Modification of the potent fibrinogen receptor (alpha(IIb)beta(3)) antagonist 1 generated compounds with high affinity for the vitronectin receptor alpha(v)beta(3). Sequential modification of the basic N-terminus of 1 led to the identification of the
Externí odkaz: https://explore.openaire.eu/search/publication?articleId=pmid________::27526919826000e62ee0beaa15c67c4c
https://pubmed.ncbi.nlm.nih.gov/11020288
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje